Clinical Trials · NCT01871844

ITF2984 Repeated Doses Study in Healthy Volunteers

CompletedPhase 1Octreotide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Italfarmaco
Enrollment
46
Start date
Jan 2012
Locations
2 sites, Italy, United Kingdom
Primary endpoint
To evaluate the effects of ITF2984 on GH, insulin, glucagon and glucose after exogenous stimulus
View Octreotide compound reference